Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (2534)	3/9/2000 9:26:00 PM
From: sandintoes	Read Replies (1) \| Respond to of 2553

But looking ahead, or going forward,using the catch phrase of the day, great things are in store for this Company! "Genzyme Surgical Products finished 1999 with solid revenue growth, improved gross margins, and strong momentum in its expanding pipeline of biomaterials and biotherapeutics," said Duke Collier, president of Genzyme Surgical Products. "We are now poised to dramatically accelerate our biosurgery strategy through our recently announced merger with Genzyme Tissue Repair and Biomatrix. The new enterprise we will create -- Genzyme Biosurgery -- will have a powerful combination of financial strength, innovative products, and leading science that is unmatched in the industry."